<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="for all cell types at three time points postinfection. TMR-001" exact="treatment" post="simultaneous with infection and 24 h postinfection effectively inhibited"/>
 <result pre="types at three time points postinfection. TMR-001 treatment simultaneous with" exact="infection" post="and 24 h postinfection effectively inhibited rabies virus release"/>
 <result pre="rabies, usually transmitted by bats [3]. In some cases, aggressive" exact="treatment" post="of the disease has been attempted in an effort"/>
 <result pre="Inc., was advanced to phase III clinical trials for mesothelioma" exact="treatment" post="[11,12]. In these trials the drug was administered to"/>
 <result pre="been completed for the topical use of ranpirnase for the" exact="treatment" post="of external genital warts caused by human papillomavirus [15]."/>
 <result pre="°C and 5.0% CO2 was infected with a multiplicity of" exact="infection" post="(MOI) = 1, incubated at 34 °C and 0.5%"/>
 <result pre="dilutions to each well in duplicate for 24 h preinfection" exact="treatment" post="and in duplicate for simultaneous treatment. Rabies virus ERA"/>
 <result pre="added at MOI = 0.1 to each well of simultaneous" exact="treatment" post="slides and in duplicate for 24 h postinfection treatment"/>
 <result pre="simultaneous treatment slides and in duplicate for 24 h postinfection" exact="treatment" post="(Figure 1). Drug-only, virus-only, and cell-only controls were prepared"/>
 <result pre="prepared in a separate eight-well slide for each treatment. Simultaneous" exact="treatment" post="slides were incubated for 48 h, while the 24"/>
 <result pre="h, while the 24 h preinfection and 24 h postinfection" exact="treatment" post="slides were incubated for 24 h at 37 °C"/>
 <result pre="10-fold serial dilutions to each well in 24 h postinfection" exact="treatment" post="slides, and RABV ERA was added at MOI ="/>
 <result pre="MOI = 0.1 to each well in 24 h preinfection" exact="treatment" post="slides. The 24 h preinfection treatment slides were incubated"/>
 <result pre="in 24 h preinfection treatment slides. The 24 h preinfection" exact="treatment" post="slides were incubated for 48 h and 24 h"/>
 <result pre="were incubated for 48 h and 24 h and postinfection" exact="treatment" post="slides were incubated 24 h at 37 °C and"/>
 <result pre="River Laboratory (Wilmington, MA, USA). Animals in the intravenous (IV)" exact="treatment" post="group underwent survival surgery at Charles River Laboratory to"/>
 <result pre="once a day, and from 7 to 21 days after" exact="infection" post="animals were observed twice daily for clinical signs of"/>
 <result pre="euthanasia. During necropsy, the brain was harvested to confirm rabies" exact="diagnosis" post="by the direct fluorescent antibody (DFA) test [26]. 2.5."/>
 <result pre="model for RABV, BSR as a comparison to in vivo" exact="testing" post="in the hamster model, and EO3E as primary cells"/>
 <result pre="2) because the untreated virus titer increased over time and" exact="treatment" post="inhibited viral release, i.e., the inhibition was more pronounced"/>
 <result pre="characterize the effect of different concentrations of TMR-001 on RABV" exact="infection" post="by choosing a single time point and cell line"/>
 <result pre="chamber slide to observe the effect of ranpirnase on virus" exact="infection" post="of the cell monolayer. TMR-001 was added to BSR"/>
 <result pre="(Figure 1). The RABV titer in the supernatant increased between" exact="treatment" post="24 h preinfection and simultaneous treatment but was similar"/>
 <result pre="the supernatant increased between treatment 24 h preinfection and simultaneous" exact="treatment" post="but was similar for simultaneous treatment and 24 h"/>
 <result pre="h preinfection and simultaneous treatment but was similar for simultaneous" exact="treatment" post="and 24 h postinfection (Figure 3a). RABV titers were"/>
 <result pre="IC50 was 2 nM, 0.4 nM, and 0.2 nM for" exact="treatment" post="24 h preinfection, simultaneous, and 24 h postinfection, respectively."/>
 <result pre="virus released in the supernatant, the effect of ranpirnase TMR-001" exact="treatment" post="on RABV cell-to-cell infection in BSR cells was also"/>
 <result pre="supernatant, the effect of ranpirnase TMR-001 treatment on RABV cell-to-cell" exact="infection" post="in BSR cells was also measured by counting the"/>
 <result pre="replication cycle for RABV strain ERA. Using this method, all" exact="treatment" post="groups had decreased cell-to-cell infection with increasing amounts of"/>
 <result pre="ERA. Using this method, all treatment groups had decreased cell-to-cell" exact="infection" post="with increasing amounts of TMR-001, with almost no cell-to-cell"/>
 <result pre="infection with increasing amounts of TMR-001, with almost no cell-to-cell" exact="infection" post="observed at the highest concentrations (Figure 3b). Of the"/>
 <result pre="observed at the highest concentrations (Figure 3b). Of the three" exact="treatment" post="groups, 24 h postinfection had consistently lower cell-to cell"/>
 <result pre="treatment groups, 24 h postinfection had consistently lower cell-to cell" exact="infection" post="at each concentration. The IC50 for cell-to-cell infection was"/>
 <result pre="cell-to cell infection at each concentration. The IC50 for cell-to-cell" exact="infection" post="was 600 nM, 100 nM, and 20 nM for"/>
 <result pre="and 24 h postinfection treatment, respectively. The amount of cell-to-cell" exact="infection" post="was not significantly different between the different treatment time"/>
 <result pre="of cell-to-cell infection was not significantly different between the different" exact="treatment" post="time points (two-way ANOVA Tukey’s adjusted p-values &amp;gt; 0.05)."/>
 <result pre="0.05). Since both RABV release into the supernatant and cell-to-cell" exact="infection" post="were inhibited, the efficacy of ranpirnase to prevent rabies"/>
 <result pre="assessed. First, a pilot study was completed to ensure TMR-001" exact="treatment" post="in uninfected animals did not cause any unexpected toxicity"/>
 <result pre="observed that a strain of mice resistant to rabies virus" exact="infection" post="had higher ribonuclease activity in the peripheral blood leucocytes"/>
 <result pre="that the broad-spectrum antiviral ranpirnase inhibits RABV release and cell-to-cell" exact="infection" post="in vitro. RABV release was inhibited in a dose-dependent"/>
 <result pre="the brain by 5-6 days postinfection [28]. Thus, the 10-day" exact="treatment" post="window covers RABV entry, transit to the CNS, and"/>
 <result pre="found only injection of 5 mg/kg at the site of" exact="infection" post="was prophylactic [29]. If this class of drugs is"/>
 <result pre="linked to other proteins or antibodies to better target RABV" exact="infection" post="[34]. Future studies could incorporate changes to TMR-001, increased"/>
 <result pre="of utmost importance due to the high lethality of natural" exact="infection" post="and dearth of medical countermeasures once symptoms manifest. Acknowledgments"/>
 <result pre="epidemiological trends, and paradigm shiftsCurr. Infect. Dis. Rep.20121440842210.1007/s11908-012-0268-222699971 4.WilloughbyR.E.Jr.TievesK.S.HoffmanG.M.GhanayemN.S.Amlie-LefondC.M.SchwabeM.J.ChusidM.J.RupprechtC.E.Survival after" exact="treatment" post="of rabies with induction of comaN. Engl. J. Med.20053522508251410.1056/NEJMoa05038215958806"/>
 <result pre="Am. Soc. Clin. Oncol.200019577a 13.PortaC.PaglinoC.MuttiL.Ranpirnase and its potential for the" exact="treatment" post="of unresectable malignant mesotheliomaBiologics2008260160910.2147/BTT.S238319707441 14.PavlakisN.VogelzangN.J.Ranpirnase—An antitumour ribonuclease: Its potential"/>
 <result pre="of an antitumor ribonuclease to Purkinje neuronsJ. Neurosci.19941453854410.1523/JNEUROSCI.14-02-00538.19948301353 32.DufkovaL.SirmarovaJ.SalatJ.HonigV.PalusM.RuzekD.FooksA.R.MansfieldK.L.TordoN.JochmansD.et al.Mannitol" exact="treatment" post="is not effective in therapy of rabies virus infection"/>
 <result pre="al.Mannitol treatment is not effective in therapy of rabies virus" exact="infection" post="in miceVaccine2019374710471410.1016/j.vaccine.2017.12.02829274698 33.ChopineauJ.RobertS.FenartL.CecchelliR.LagoutteB.PaitierS.DehouckM.P.DomuradoD.Monoacylation of ribonuclease A enables its transport"/>
 <result pre="https://rabiesalliance.org/resource/bat-rabies-outbreak-peru-claims-one-others-survive-mass-vaccination-campaign-underway(accessed on 20 September 2018) 37.BanyardA.C.MansfieldK.L.WuG.SeldenD.ThorneL.BirchC.KorakaP.OsterhausA.FooksA.R.Re-evaluating the effect of Favipiravir" exact="treatment" post="on rabies virus infectionVaccine2019374686469310.1016/j.vaccine.2017.10.10929132993 38.MarosiA.DufkovaL.ForroB.FeldeO.ErdelyiK.SirmarovaJ.PalusM.HonigV.SalatJ.TikosR.et al.Combination therapy of rabies-infected"/>
 <result pre="Res.201917210464110.1016/j.antiviral.2019.10464131672666 41.MechliaM.B.BelaidA.CastelG.JalletC.MansfieldK.L.FooksA.R.HaniK.TordoN.Dermaseptins as potential antirabies compoundsVaccine2019374694470010.1016/j.vaccine.2018.01.06629439871 Figure 1 Time of" exact="treatment" post="method. For cells treated 24 h preinfection, BSR cells"/>
 <result pre="postinfection. Figure 3 Inhibition of rabies virus release and cell-to-cell" exact="infection" post="regardless of TMR-001 treatment time. TMR-001 was added at"/>
 <result pre="of rabies virus release and cell-to-cell infection regardless of TMR-001" exact="treatment" post="time. TMR-001 was added at the given concentrations to"/>
 <result pre="cells (BSR) at 24 h preinfection (blue circle), simultaneously to" exact="infection" post="(red square), or 24 h postinfection (green triangle). The"/>
 <result pre="monolayer was fixed at 48 h postinfection, and relative cell-to-cell" exact="infection" post="was measured by counting clusters of fluorescent foci using"/>
 <result pre="20 nM for 24 h postinfection. The amount of cell-to-cell" exact="infection" post="was not significantly different between the different treatment time"/>
 <result pre="of cell-to-cell infection was not significantly different between the different" exact="treatment" post="time points (two-way ANOVA Tukey’s adjusted p-values &amp;gt; 0.05)."/>
 <result pre="(two-way ANOVA Tukey’s adjusted p-values &amp;gt; 0.05). Figure 4 TMR-001" exact="treatment" post="does not prevent rabies in Syrian hamsters. Starting 24"/>
 <result pre="(IP, green), intramuscularly (IM, red), intravenously (IV, blue), or no" exact="treatment" post="(purple), once per day for 10 days. Group size"/>
</results>
